Experience of a Pediatric Oncology Clinical Research Center in Brazil. Antonio Sergio Petrilli, MD, PhD

Size: px
Start display at page:

Download "Experience of a Pediatric Oncology Clinical Research Center in Brazil. Antonio Sergio Petrilli, MD, PhD"

Transcription

1 Experience of a Pediatric Oncology Clinical Research Center in Brazil Antonio Sergio Petrilli, MD, PhD

2 Children and adolescents Heterogeneous in many aspects 38% of Brazilian population (IBGE, 2000) 11,530 new cases of cancer/year (<20 years) (INCA, 2012)

3 Clinical Research in Pediatric Oncology - Challenges Too few kids Unlicensed and off label drug use over 50 % of the medicines used for children had not been tested for use in this age group since 2008: more than 600 pediatric investigation plans have been approved Develop cooperative groups Training human resources Funding Improve regulatory environment PROGRESS REPORT ON THE PAEDIATRIC MEDICINE REGULATION 2007 (2013) Average time to approval (IOP-GRAACC/UNIFESP, Brazil): 8-16m Boklan, Mol Cancer Ther, 2006 Conroy, Annals of Oncology, 2003

4 Clinical Research in Pediatric Oncology - Challenges Promote collaboration between industry, academia and government Academy: fostering research, publications Industry: reduce drug lag,strengthen pipelines,generates spill over effect Government: economic benefit,setting of global level standard Only 10% of 15-to-19 year old adolescent cancer patients are entered into trials, compared to 60% of those under the age of 15 (NCI, 2008)

5 Mortality rate reduction Epidemiology Mortality Rate Reduction U.S.A % 2.8% 2.6% Média Anual em % 2% 1% Why? 1.8% 1.5% 0.9% 1.1% 1.5% 0.4% 0% Age (year) Idade (Anos) Bleyer, W.A. The impact of childhood cancer on the United States and the world Ca,40: ,1990; Bleyer, W.A th ASCO 2000 Conference

6 Participation in Clinical trials Epidemiology Enrollment in NCI-Sponsored Trials ( ) Idade (Anos) Age (year) Bleyer, W.A. The impact of childhood cancer on the United States and the world Ca,40: ,1990; Bleyer, W.A th ASCO 2000 Conference

7 Mortality rate reduction Mortality rate reduction Participation in Clinical trials Epidemiology Rate of participation in U.S. clinical trials and mortality ( ) 25% 3% 20% 15% % 2% 5% 0% r =.91, p =.001 1,000 10,000 Participation in CT (log) % % Age (year) Bleyer, W.A. The impact of childhood cancer on the United States and the world Ca,40: ,1990; Bleyer, W.A th ASCO 2000 Conference

8 Clinical Research in Pediatric Oncology - Successes 5 year survival ~ 80% (SEER 2010) Parents supported by medical staff are highly motivated to enroll their kids on CT Response assessment easier in kids Development of Clinical Trials in a Cooperative Group Setting Boklan, Mol Cancer Ther,

9 IOP-GRAACC/UNIFESP - Clinical Research Department Well-trained infrastructure: Dedicated medical personnel Study coordinators, nurse and pharmacist Data manager, statistical support Electronic data capture for institutional protocols Full regulatory support Archiving facilities

10 IOP-GRAACC/UNIFESP - Studies Year # Institutional # Sponsored # Participants Total Average Accrual studies ongoing Study A Study B Study C Study D Study E Study F Commited Included Feasibilities 7/13 (53%) 5/11 (45%) 1/9 (11%) 10

11 IOP-GRAACC/UNIFESP-Multicenter Clinical Trials COG clinical trials: adrenocortical carcinoma, hepatoblastoma, retinoblastoma Drug development industry sponsored clinical trials (II-IV) Global Databases: Center for International Blood and Marrow Transplant Research (CIBMTR) Paediatric Fungal Network (PFN) Investigator Initiated Trials (IITs): CNS and bone tumors, infectology

12 IOP-GRAACC/UNIFESP - Translational Research Genetic and Molecular Biology Laboratory Investigation of tumor markers and therapeutic targets Tissue Bank Consortium Tests in OS cell lines Tumor Patients Samples BST CNS Leukemia Neuroblastic Wilms Lymphoma GCT Liver Retinoblastoma 5 12 Langerhans 7 18 Melanoma 2 9 Miscelanea Total

13 Cutting edge research Clinical Research Genetics and Genomics Clinical data Adams, J.U, Building the bridge from bench to bedside, Nature Reviews Drug Discovery, June 2008

14 Brazilian Osteosarcoma Treatment Group (BOTG) Created in 1980 s 5 consecutive studies completed Beginning: small number of patients enrolled few specialized institutions in a single city (SP) Study V: 25 institutions from 9 states and 15 different cities 368 patients enrolled

15

16 At present Latin American Group of Osteosarcoma Treatment Multicentric, randomized study with data collection over 32 sites in Latin America Self-maintained Generate information on lower cost treatments

17 Latin American Group of Osteosarcoma Treatment Objectives: Evaluate if HD-MTX, CDDP and Doxorubin will improve EFS of patients with resectable osteosarcoma Investigate the impact of metronomic treatment on EFS of non-metastatic and metastatic osteosarcoma patients

18 Osteosarcoma 2006 Protocol Non Metastatic

19 Osteosarcoma 2006 Protocol Non Metastatic

20 Osteosarcoma 2006 Protocol Metastatic

21 Overall survival N=655 A) - Non Metastatic Arm 1 (no metronomic) B) - Non Metastatic Arm 2 (with metronomic) C) Metastatic (with metronomic) D) Non Metastatic (no randomization) E) Metastatic (no metronomic) 2y 5y n A B C D E

22 Value of a shared protocol OS outcomes in 2 centers Relapse Refusal Progression Toxic death Refusal Relapse Toxic death Progression Center 1 Center 2

23 Childhood Cancer Survival 90 High-income vs. low middle-income countries Survival gap High-income countries Low middle-income countries

24 At IOP-GRAACC/UNIFESP Survival gap closing in GRAACC, Brazil Survival gap High-income countries IOP/GRAACC-UNIFESP Low middle-income countries

25 Our contacts Coordinating Site Prof. Dr. Antonio Sérgio Petrilli Dra. Andreza A. Senerchia Arnaldo Pires Mariane Diniz Raquel Passos Thais Rodrigues Tel: Fax :

Pediatric Trials in Latin America Clinical Research in Pediatric Oncology

Pediatric Trials in Latin America Clinical Research in Pediatric Oncology Pediatric Trials in Latin America Clinical Research in Pediatric Oncology Prof. Dr. Antonio Sérgio Petrilli Clinical Research Regulations Timeline Best Pharmaceuticals for Children Act estabilished programme

More information

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute

More information

Joy Bartholomew RN, MSN, FNP-BC, CPON

Joy Bartholomew RN, MSN, FNP-BC, CPON Joy Bartholomew RN, MSN, FNP-BC, CPON Experience 1996-Present 3/05-Present Nurse Practitioner/Nurse Case Manager in Hematology/Oncology Children s Mercy Hospital and Clinics. Firstat Nursing services PRN.

More information

White Paper. Understanding the Scope and Challenges of Childhood Cancer. Introduction

White Paper. Understanding the Scope and Challenges of Childhood Cancer. Introduction White Paper Understanding the Scope and Challenges of Childhood Cancer Introduction Imagine a world without childhood cancer. No painful chemotherapy treatments. No emotional stress on children and their

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

New Hampshire Childhood Cancer

New Hampshire Childhood Cancer Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Overcoming cancer with research Vienna 15 th -17 th May, 2008. Session 3: Established therapeutic compounds

Overcoming cancer with research Vienna 15 th -17 th May, 2008. Session 3: Established therapeutic compounds Overcoming cancer with research Vienna 15 th -17 th May, 2008 Session 3: Established therapeutic compounds Introduction Randomized clinical trials: bedrock of progress in children with cancer in the last

More information

NCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital

NCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital A. Name and location of hospital:, Indianapolis, IN B. Name of cancer center: St. Vincent Oncology Center C. Identify PI and key personnel with contact information for each pilot focus areas: a. Disparities

More information

THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY. Jeff Allen, PhD Executive Director Friends of Cancer Research

THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY. Jeff Allen, PhD Executive Director Friends of Cancer Research THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY Jeff Allen, PhD Executive Director Friends of Cancer Research Current Challenges Each potential new therapy is typically tested independently

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Cancer Clinical Trials: In-Depth Information

Cancer Clinical Trials: In-Depth Information Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information

Future Directions in Cancer Research What does is mean for medical physicists and AAPM?

Future Directions in Cancer Research What does is mean for medical physicists and AAPM? Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman

More information

A model applicable to other disciplines?

A model applicable to other disciplines? Conducting Phase 1 studies in Pediatric Oncology A model applicable to other disciplines? Sylvain Baruchel MD New Agent and Innovative Therapy Program Toronto Hospital For Sick Children MILESTONES IN PEDIATRIC

More information

Clinical Research Program Information for Patients. Transplant Creations

Clinical Research Program Information for Patients. Transplant Creations Clinical Research Program Information for Patients Transplant Creations 1 Program Focus Combination chemotherapy and transplantation of stem cells from an autologous donor (patient s own stem cells) and/or

More information

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:

More information

National Cancer Institute

National Cancer Institute National Cancer Institute An Analysis of the National Cancer Institute s Investment in Pediatric Cancer Research September 2013 U.S. Department of Health and Human Services National Institutes of Health

More information

Teaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013

Teaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013 Teaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013 Disclosures I have no disclosures But. I have a WARNING: This talk is largely

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant 2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:

More information

MEDIDATA/RAVE. from A Biostatistician s Perspective

MEDIDATA/RAVE. from A Biostatistician s Perspective MEDIDATA/RAVE from A Biostatistician s Perspective Presented by: Mehmet Kocak, Ph.D. Assistant Professor at, UTHSC Resources: www.ctsu.org www.mdsol.com Report of the Clinical Trials Working Group of the

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops

More information

Clinical Trials: Questions and Answers

Clinical Trials: Questions and Answers Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which

More information

Cancer Services for Adults and Children

Cancer Services for Adults and Children UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer

More information

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Clinical trial enrollment among older cancer patients

Clinical trial enrollment among older cancer patients Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department

More information

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

The Evolving Role of Nurses in Early Phase Research

The Evolving Role of Nurses in Early Phase Research U.S. Department of Health and Human Services The Evolving Role of Nurses in Early Phase Research Clare Hastings, RN, PhD, FAAN Chief Nurse Officer, Clinical Center April 27, 2012 Discover America s Research

More information

Site Selection: Lessons from Cancer Clinical Trials

Site Selection: Lessons from Cancer Clinical Trials 1 Site Selection: Lessons from Cancer Clinical Trials Presentation by John Eckardt, MD Chief Medical Officer Phone: 214.451.4520 jeckardt@davaonc.com SCOPE Annual Meeting Tuesday, February 7, 2012 DAVAOncology,

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

Effective Advocate Participation in The Clinical Trial Process

Effective Advocate Participation in The Clinical Trial Process Effective Advocate Participation in The Clinical Trial Process Peggy Devine Founder & Executive Director Cancer Information & Support Network (CISN) Ovarian Cancer National Alliance Conference September

More information

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology INTRODUCTION 2009 A university wishing to have an accredited program in Pediatric Hematology/Oncology must also

More information

Mayo Clinic College of Medicine Pharmacy Services. Rotation Summary

Mayo Clinic College of Medicine Pharmacy Services. Rotation Summary Mayo Clinic College of Medicine Pharmacy Services Rotation Summary Rotation Title: PGY-2 Pediatric Hematology-Oncology Rotation Length: 3-6 weeks Primary Preceptor Name: Amanda Kuper, PharmD, BPCS, Ron

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Role of clinical trials in professional development

Role of clinical trials in professional development Role of clinical trials in professional development Peeter Padrik Tartu University Hospital University of Tartu Estonian Society for Medical Oncology How we do treatment decisions? Personal experience?

More information

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146 Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer

More information

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome A service of the U.S. National Institutes of Health Trial record 1 of 5 for: efficacy of PF-04449913 Previous Study Return to List Next Study A Study To Evaluate PF-04449913 With Chemotherapy In Patients

More information

Choosing a Blood Cancer Specialist or Treatment Center

Choosing a Blood Cancer Specialist or Treatment Center Choosing a Blood Cancer Specialist or Treatment Center No. 6 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

Introduction to Data Auditing

Introduction to Data Auditing How did we get here?? Introduction to Data Auditing David Hurd, M.D. Interim Chair, Data Audit Committee Wake Forest University School of Medicine CALGB Audit Preparation Workshop, June 2007 National Cancer

More information

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its

More information

68 th Meeting of the National Cancer Institute (NCI) NCI Council of Research Advocates (NCRA) National Institutes of Health (NIH)

68 th Meeting of the National Cancer Institute (NCI) NCI Council of Research Advocates (NCRA) National Institutes of Health (NIH) 68 th Meeting of the National Cancer Institute (NCI) NCI Council of Research Advocates (NCRA) National Institutes of Health (NIH) Updates on NCI Programs Building 31, C Wing, Conference Room 6 NIH Campus

More information

ACUTE LYMPHOBLASTIC LEUKEMIA ~ STUDY #1

ACUTE LYMPHOBLASTIC LEUKEMIA ~ STUDY #1 ACUTE LYMPHOBLASTIC LEUKEMIA ~ STUDY #1 Title: COG AALL06N1: A Study of Neurocognitive Function in Children Treated for ALL. Purpose: To determine the effects, if any, of methotrexate, on learning skills

More information

BIOBANKING a challenge for public / private partnerships. Christian Bréchot

BIOBANKING a challenge for public / private partnerships. Christian Bréchot BIOBANKING a challenge for public / private partnerships Christian Bréchot Patient Disease Diagnosis Targeted Personalized therapies Risk medecine prediction Biomarker Diagnostic Theranostic: Efficay Toxicity

More information

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission

More information

IDE Requirements for Diagnostic Tests Used in Clinical Trials

IDE Requirements for Diagnostic Tests Used in Clinical Trials IDE Requirements for Diagnostic Tests Used in Clinical Trials J. Milburn Jessup, MD Diagnostics Evaluation Branch Cancer Diagnosis Program DCTD, NCI, NIH jessupj@mail.nih.gov Outline Background Uses of

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

Clinical Cancer Research: Alternative IRB Models and Enhancing Progress

Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical

More information

American Cancer Society Extramural Grants

American Cancer Society Extramural Grants Page: 1 Graduate Scholarships in Cancer Nursing Practice (GSCNP) GSCNP-15-122-01 Walker, Danielle, BSN MENTOR: McMillan, Susan, PhD University of South Florida College of Nursing Graduate Scholarship in

More information

Impact of the Guatemalan Nursing Program on Treatment Abandonment in Children with Cancer

Impact of the Guatemalan Nursing Program on Treatment Abandonment in Children with Cancer Impact of the Guatemalan Nursing Program on Treatment Abandonment in Children with Cancer Sara W. Day, PhD, RN, FAAN Rita M. Carty, PhD, RN, FAAN Leslie M. McKeon, PhD, RN Childhood Cancer in Developing

More information

What is Cancer? Section 2 - What Is Cancer? - 1 -

What is Cancer? Section 2 - What Is Cancer? - 1 - What is Cancer? Normal Growth The human body is made up of many millions of tiny building blocks called cells. Each organ of the body (eg. brain, liver, muscle) contains its own special types of cells,

More information

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine Stem Cells and Inner Ear Cell Regeneration Stefan Heller Stanford University School of Medicine Embryonic stem cells Induced pluripotent stem cells Somatic stem cells 50 µm Derived from the inner cell

More information

Cancer in Children. What is cancer?

Cancer in Children. What is cancer? What is cancer? Cancer in Children The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly fashion. During the early years of a person

More information

Connection. CIBMTR Clinical Research Associates Mentoring Committee

Connection. CIBMTR Clinical Research Associates Mentoring Committee Newsletter: Data Connection CIBMTR Clinical Research Associates Mentoring Committee Friday, September 12, 2008 Mark your calendars for the 2009 BMT Tandem Meeting. It will be held at the Tampa Convention

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Pediatric Hematology-Oncology Fellowship Training Program

Pediatric Hematology-Oncology Fellowship Training Program Pediatric Hematology-Oncology Fellowship Training Program The Children s Hospital at Montefiore Albert Einstein College of Medicine-Montefiore Medical Center SUMMARY......Page 2 PROGRAM GOALS AND OBJECTIVES......Page

More information

4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma

4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer

More information

CORD BLOOD BANKING IN BRAZIL HOSPITAL ISRAELITA ALBERT EINSTEIN S EXPERIENCE

CORD BLOOD BANKING IN BRAZIL HOSPITAL ISRAELITA ALBERT EINSTEIN S EXPERIENCE CORD BLOOD BANKING IN BRAZIL HOSPITAL ISRAELITA ALBERT EINSTEIN S EXPERIENCE JOSÉ MAURO KUTNER, MD MEDICAL DIRECTOR BLOOD BANK Brazil - South America BARCELONA * * SÃO PAULO Brazil - South America Brazil

More information

30 Nature Methods 31 Nature Microbiology 32 Nature Nanotechnology 33 Nature Neuroscience 34 Nature Photonics 35 Nature Physics 36 Nature Plants 37

30 Nature Methods 31 Nature Microbiology 32 Nature Nanotechnology 33 Nature Neuroscience 34 Nature Photonics 35 Nature Physics 36 Nature Plants 37 Nature titles Journal 1 Nature 2 Nature Reviews Cancer 3 Nature Reviews Cardiology 4 Nature Reviews Clinical Oncology 5 Nature Reviews Disease Primers 6 Nature Reviews Drug Discovery 7 Nature Reviews Endocrinology

More information

Moving forward, where are we with Clinical Trials?

Moving forward, where are we with Clinical Trials? Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where

More information

Yale Cancer Center Data and Safety Monitoring Committee Charter

Yale Cancer Center Data and Safety Monitoring Committee Charter Yale Cancer Center Data and Safety Monitoring Committee Charter Purpose/Mission The purpose of the Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) is to provide ongoing data and safety

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer

Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Options for Endpoints First-Line Trials in Advanced OVCA Overall Survival:

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director Stuart Klein, MHA Executive Director Zuofeng Li, DSc Physics Director

Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director Stuart Klein, MHA Executive Director Zuofeng Li, DSc Physics Director Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director A University of Florida College of Medicine faculty member since 1985, Dr. Mendenhall served as the chair of the Department

More information

Special Section: Cancer in Children & Adolescents

Special Section: Cancer in Children & Adolescents Special Section: Cancer in Children & Adolescents Overview The news of a cancer diagnosis is never welcome, but may be even more unexpected and difficult when the disease is diagnosed in a child or adolescent.

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

What Cancer Patients Need To Know

What Cancer Patients Need To Know Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC

More information

Florida Clinical Trials Agreement

Florida Clinical Trials Agreement Florida Clinical Trials Agreement Agreement to Reduce Cancer Morbidity and Mortality in Florida The undersigned parties to this Florida Clinical Trials Agreement (Agreement) acknowledge that Florida ranks

More information

Technology funding opportunities at the National Cancer Institute

Technology funding opportunities at the National Cancer Institute Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer

More information

Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments

Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments Cancer Patients Urgently Need Effective, Genetically-Targeted Treatments The Core Problem One Symptom, Not One Disease The disease we call cancer is the second most common cause of death in the United

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

American Cancer Society Extramural Grants

American Cancer Society Extramural Grants Page: 1 Graduate Scholarships in Cancer Nursing Practice (GSCNP) GSCNP-14-118-01 Abbott, Linda, MSN MENTOR: Hooke, Mary C., PhD, RN School of Nursing Graduate Scholarship in Cancer Nursing Practice 07/01/2014

More information

The National Institute of Genomic Medicine (INMEGEN) was

The National Institute of Genomic Medicine (INMEGEN) was Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the

More information

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety,

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate

More information

Survivorship Care Plans Guides for Living After Cancer Treatment

Survivorship Care Plans Guides for Living After Cancer Treatment Survivorship Care Plans Guides for Living After Cancer Treatment Institute of Medicine Report 2005 Recommendations for meeting needs of cancer survivors Implement survivorship care plan Build bridges

More information

CURESEARCH FOR CHILDREN S CANCER AND GATEWAY FOR CANCER RESEARCH COMMUNITY IMPACT AWARD - CLINICAL TRIALS

CURESEARCH FOR CHILDREN S CANCER AND GATEWAY FOR CANCER RESEARCH COMMUNITY IMPACT AWARD - CLINICAL TRIALS KEY DATES Request for Applications Opens: June 3, 2015 Application Due: August 3, 2015 Award Notification: September 2015 Award Period : October 2015 October 2016 CURESEARCH FOR CHILDREN S CANCER AND GATEWAY

More information

Senate Financial Institutions & Insurance Committee: SB 629 Coverage for Routine Care Associated with Cancer Clinical Trials

Senate Financial Institutions & Insurance Committee: SB 629 Coverage for Routine Care Associated with Cancer Clinical Trials Senate Financial Institutions & Insurance Committee: SB 629 Coverage for Routine Care Associated with Cancer Clinical Trials February 26, 2008 Marcia Nielsen, PhD, MPH Executive Director Kansas Health

More information

Challenges in assessing disease latency for cancer in environmental epidemiology

Challenges in assessing disease latency for cancer in environmental epidemiology Challenges in assessing disease latency for cancer in environmental epidemiology Peggy Reynolds, Ph.D. Case-only Clustering in Mobile Populations Workshop - November 11-12, 2010 Ann Arbor, Michigan Outline

More information

Obtaining Funding in Clinical Research

Obtaining Funding in Clinical Research Obtaining Funding in Clinical Research Ellen Seely, MD Director of Clinical Research Endocrinology, Diabetes and Hypertension Division Vice Chair, Faculty Development, Department of Medicine Brigham and

More information